MARKET INSIGHTS
Global induced pluripotent stem cells (iPSC) service market was valued at USD 2.45 billion in 2023 and is projected to reach USD 5.11 billion by 2030, growing at a CAGR of 11.3% during the forecast period. This robust growth is driven by increasing applications in regenerative medicine and pharmaceutical research.
Induced pluripotent stem cell services encompass a suite of specialized techniques for reprogramming adult somatic cells into pluripotent stem cells, which can differentiate into any cell type. These services include iPSC manufacturing, reprogramming, culture, differentiation, and gene editing - all critical components for advancing personalized medicine and disease modeling. The technology's ability to bypass ethical concerns associated with embryonic stem cells has further accelerated adoption.
The market expansion is fueled by rising R&D investments from pharmaceutical companies and research institutions, particularly in drug discovery and toxicity testing applications. North America currently dominates the market, while Asia-Pacific shows the fastest growth potential due to increasing government support for stem cell research. Key players like Lonza and Thermo Fisher Scientific are expanding their service portfolios through strategic collaborations and technological innovations in iPSC derivation and characterization.
MARKET DYNAMICS
MARKET DRIVERS
Expansion in Regenerative Medicine to Fuel iPSC Service Demand
The global regenerative medicine market, valued at over $15 billion in 2023, is creating significant demand for iPSC services as researchers seek innovative solutions for tissue repair and organ regeneration. Induced pluripotent stem cells offer unprecedented potential because they can differentiate into any cell type while avoiding the ethical concerns associated with embryonic stem cells. Pharmaceutical companies are increasingly investing in iPSC-based therapies, with over 150 clinical trials currently underway for conditions ranging from Parkinson's disease to heart failure. This therapeutic potential directly drives growth across all iPSC services, particularly manufacturing and differentiation services which are essential for developing these treatments.
Advancements in Drug Discovery Platforms Accelerate Market Growth
The pharmaceutical industry's shift toward more predictive preclinical models is transforming drug discovery workflows, with iPSCs emerging as a critical component. These cells enable creation of disease-specific models that more accurately reflect human biology compared to traditional animal models. Recent technological breakthroughs in differentiation protocols have reduced variability in iPSC-derived cell populations, increasing their reliability for high-throughput screening. Furthermore, the ability to create patient-derived iPSC lines allows for population-specific drug testing, addressing long-standing challenges in clinical trial success rates. This has led to double-digit annual growth in contract research organizations offering customized iPSC services to pharma clients.
Strategic Collaborations Between Academia and Industry
The market is witnessing increased partnerships between research institutions and commercial service providers, creating a robust pipeline for innovation. Several universities holding foundational iPSC patents have established technology transfer programs and spin-off companies to commercialize their research. Such collaborations provide service providers access to cutting-edge methodologies while offering academic institutions commercialization pathways for their discoveries. The resulting symbiosis accelerates technology transfer and expands the range of available specialized services, from niche differentiation protocols to advanced gene editing capabilities.
MARKET RESTRAINTS
Stringent Regulatory Frameworks Limit Commercial Adoption
While iPSC technologies show tremendous potential, navigating complex regulatory landscapes remains a significant barrier to market expansion. Regulatory bodies classify iPSC-derived products as advanced therapy medicinal products (ATMPs), subjecting them to rigorous evaluation processes that can extend development timelines by several years. The lack of standardized global regulations further complicates matters, as companies must tailor submissions to regional requirements. These challenges are particularly acute for gene-edited iPSC lines, where regulatory agencies often require extensive safety data beyond standard stem cell products.
Technical Limitations in Large-Scale Manufacturing
Scaling iPSC production while maintaining quality and consistency presents substantial technical challenges. Current manufacturing methods often struggle to produce clinically-relevant quantities of differentiated cells, with issues including batch-to-batch variability and incomplete differentiation. Automation and quality control systems used for traditional biologics frequently require significant adaptation for iPSC applications. These technical hurdles increase production costs and limit the commercial viability of iPSC-based therapies, particularly for common conditions requiring large patient populations.
Intellectual Property Complexity
The iPSC field contends with a fragmented intellectual property landscape featuring overlapping patents held by various institutions. This creates uncertainty for service providers developing new offerings, as they must navigate complex licensing arrangements. The situation is further complicated by jurisdictional differences in patent enforcement and expiration timelines. These factors discourage some potential market entrants and can delay the commercialization of new technologies while patent disputes are resolved.
MARKET OPPORTUNITIES
Emerging Applications in Personalized Medicine Create New Revenue Streams
The convergence of iPSC technology with personalized medicine represents a significant growth opportunity, particularly in oncology and rare diseases. Clinics now offer services to bank patient-specific iPSC lines for potential future therapeutic use—a market segment projected to triple over the next five years. Additionally, pharmaceutical companies increasingly utilize patient-derived iPSCs to identify responders and non-responders during drug development, improving clinical trial success rates. These applications create demand for specialized service offerings including genetic characterization, differentiation, and functional validation of patient-specific cell lines.
Advancements in Automated Cell Culture Systems Open New Possibilities
Recent developments in automated cell culture and quality control technologies enable more consistent and cost-effective iPSC service provision. Robotic systems now available can maintain hundreds of iPSC lines simultaneously with minimal manual intervention, while AI-powered image analysis improves quality assessment. These technologies allow service providers to scale operations without proportional increases in labor costs. Furthermore, they facilitate standardization—a critical factor for scientific reproducibility and regulatory approval—making them attractive to both research and therapeutic clients.
Growing Strategic Investments in Asia-Pacific Markets
While North America and Europe currently dominate the iPSC services market, the Asia-Pacific region presents untapped potential with its combination of progressive regulatory environments and significant government funding for stem cell research. Countries like Japan, South Korea, and China have implemented streamlined approval pathways for regenerative medicine products—some offering conditional approval based on limited clinical data. This has prompted multinational service providers to establish regional hubs and form partnerships with local research institutions, creating new revenue opportunities while diversifying geographical risk.
MARKET CHALLENGES
High Costs and Long Timelines for Service Delivery
The specialized nature of iPSC services results in significant costs that can deter potential clients, particularly academic researchers with limited funding. Developing a clinically-compliant iPSC line typically requires six to twelve months and substantial investment in quality control measures. For gene editing services, the timeline extends further due to the need for extensive validation. These factors create pricing pressures as clients weigh the benefits against the substantial investment required, particularly when considering custom projects rather than standardized service offerings.
Talent Shortage in Specialized Cell Biology Fields
The industry faces a critical shortage of researchers and technicians with expertise in both stem cell biology and Good Manufacturing Practice (GMP) compliance. This skills gap limits the ability of service providers to scale operations and meet growing demand. Specialized training programs remain rare, forcing companies to invest heavily in internal training initiatives. The situation is exacerbated by competition for talent from pharmaceutical companies and academia, leading to high turnover rates that disrupt service continuity and quality assurance processes.
Storage and Distribution Complexities
Maintaining and shipping live iPSC products introduces logistical challenges that impact service reliability. The cells require specialized storage conditions at ultra-low temperatures while remaining vulnerable to freeze-thaw cycles during transportation. These requirements increase operational costs and complicate international distribution, particularly to regions with less developed cold chain infrastructure. Additionally, customs delays for biological materials can jeopardize cell viability, creating disputes over service guarantees and requiring repeat work that strains provider resources.
Segment Analysis:
By Type
iPSC Manufacturing Service Leads the Market Owing to Core Role in Reprogramming and Cell Line Development
The market is segmented based on type into:
-
iPSC Manufacturing Service
-
iPSC Reprogramming Service
-
iPSC Culture Service
-
iPSC Differentiation Service
-
iPSC Gene Editing Service
-
Other Services
By Application
Pharmaceutical Companies Dominate Demand for Drug Discovery and Toxicity Testing Applications
The market is segmented based on application into:
By End User
Research Institutions Hold Significant Share Due to Extensive Stem Cell Research Activities
The market is segmented based on end user into:
-
Pharmaceutical and biotechnology companies
-
Academic and research institutions
-
Hospitals and clinics
-
Contract research organizations
COMPETITIVE LANDSCAPE
Key Industry Players
Innovation and Strategic Collaborations Drive Market Competition
The global induced pluripotent stem cells (iPSC) service market features a dynamic competitive environment where established biotech giants and specialized service providers compete through technological differentiation. Lonza and Thermo Fisher Scientific Inc. dominate the space, leveraging their extensive infrastructure for large-scale iPSC manufacturing and global distribution networks. Their market leadership stems from integrated service offerings spanning reprogramming, differentiation, and gene editing – critical for pharmaceutical and academic clients.
FUJIFILM Cellular Dynamics, Inc. (FCDI) has emerged as a key challenger, particularly in disease modeling applications. Their proprietary episomal reprogramming technology addresses critical safety concerns regarding genetic modifications, capturing significant market share in North America and Asia. Meanwhile, Charles River Laboratories has strengthened its position through strategic acquisitions, notably expanding its iPSC-derived cell-based assay capabilities for drug discovery applications.
The market has witnessed notable fragmentation in specialized segments. Players like Axol Bioscience Ltd. differentiate through tailored iPSC-derived neuronal and cardiac cell services, while Creative Biolabs focuses on niche applications in antibody development and toxicity testing. This specialization creates multiple growth avenues within the broader market.
Investment trends reveal intense R&D focus on process automation and CRISPR-based gene editing integration. Thermo Fisher's recent launch of GMP-compliant iPSC lines and Lonza's
List of Key Induced Pluripotent Stem Cells Service Providers
-
Lonza (Switzerland)
-
Thermo Fisher Scientific Inc. (U.S.)
-
FUJIFILM Cellular Dynamics, Inc. (U.S.)
-
Charles River Laboratories (U.S.)
-
Novo Holdings (Catalent, Inc) (Denmark/U.S.)
-
Creative Bioarray (U.S.)
-
Creative Biolabs (U.S.)
-
iXCells Biotechnologies (U.S.)
-
Axol Bioscience Ltd. (UK)
-
Elixirgen Scientific, Inc. (U.S.)
INDUCED PLURIPOTENT STEM CELLS SERVICE MARKET TRENDS
Advancements in Regenerative Medicine Driving iPSC Service Adoption
The global induced pluripotent stem cells (iPSC) service market is experiencing significant growth, projected to expand from $2.45 billion in 2023 to $5.11 billion by 2030, at a compound annual growth rate of 11.3%. This surge is largely attributed to breakthroughs in regenerative medicine applications, where iPSCs are revolutionizing personalized treatments. Pharmaceutical companies and research institutions are increasingly outsourcing iPSC services to leverage specialized expertise in cell reprogramming and differentiation. The ability to generate patient-specific cell lines for disease modeling and drug testing has reduced clinical trial failures by approximately 25-30% compared to traditional methods, making these services invaluable for precision medicine development.
Other Trends
Technological Innovations in Cell Reprogramming
Recent advancements in non-viral reprogramming techniques have significantly improved the safety profile of iPSC generation, with current success rates exceeding 85% for certain cell types. The integration of CRISPR-based gene editing with iPSC services has created new opportunities for disease modeling and therapeutic development. These technologies enable researchers to create isogenic cell lines with specific genetic modifications, accelerating drug discovery timelines by 40-50%. Furthermore, automated cell culture systems are reducing manual intervention in iPSC maintenance, improving reproducibility across laboratories while cutting operational costs by nearly 30%.
Expanding Applications in Neurological and Cardiovascular Research
The pharmaceutical industry's growing focus on neurological disorders and cardiovascular diseases is creating substantial demand for iPSC differentiation services. Recent data indicates that over 60% of preclinical CNS drug development programs now incorporate iPSC-derived neurons for toxicity screening. Similarly, cardiac applications have seen remarkable growth, with iPSC-derived cardiomyocytes becoming the gold standard for arrhythmia studies. This shift is supported by improved differentiation protocols that now achieve 90-95% purity for specific cell lineages, enabling more accurate disease modeling and reducing the need for animal testing in accordance with evolving regulatory guidelines.
Regional Analysis: Induced Pluripotent Stem Cells (iPSC) Service Market
North America
North America dominates the iPSC services market, with the U.S. contributing the majority share due to robust biotechnology infrastructure and strong R&D investments. The region benefits from well-established pharmaceutical companies, academic institutions, and government funding for regenerative medicine. The National Institutes of Health (NIH) allocated over $2.6 billion for stem cell research in 2023, accelerating advancements in iPSC technologies. Stringent FDA regulations ensure high-quality standards, though compliance costs remain a challenge for smaller firms. The increasing demand for personalized medicine and disease modeling further drives growth.
Europe
Europe maintains a significant presence in the iPSC services market, supported by strong regulatory frameworks like EU Clinical Trials Regulation and Horizon Europe funding programs. Countries such as Germany and the UK lead in innovation due to collaborations between academic research centers and biotech firms. The European Medicines Agency (EMA) has approved several iPSC-based clinical trials, highlighting the region’s progressive stance. However, fragmented reimbursement policies and ethical concerns regarding gene editing limit rapid scaling of iPSC therapies. Despite this, Europe remains a hub for translational research in neurodegenerative and cardiovascular diseases.
Asia-Pacific
The Asia-Pacific region exhibits the highest growth potential, propelled by China’s aggressive investments in regenerative medicine and Japan’s pioneering role in iPSC commercialization. China’s 14th Five-Year Plan emphasizes biotech development, with iPSC-based therapies gaining traction in clinical applications. Japan, home to Nobel laureate Shinya Yamanaka (pioneer of iPSC technology), boasts streamlined regulatory pathways for regenerative medicine approvals. India and South Korea are emerging as key players, leveraging cost-competitive research environments. However, inconsistent regulatory standards and intellectual property challenges hinder broader adoption across the region.
South America
South America shows gradual but promising developments in iPSC services, primarily led by Brazil and Argentina. Local governments are increasing funding for stem cell research, particularly in treating chronic diseases prevalent in the region. Clinical trials for iPSC-derived therapies are gaining momentum, though limited infrastructure and scarce skilled labor hinder progress. Economic volatility often redirects funding away from long-term biotech projects, but partnerships with North American and European firms provide growth opportunities.
Middle East & Africa
The Middle East & Africa represent an emerging market with Israel and Saudi Arabia at the forefront of iPSC research. Israel’s strong academic-industry collaborations have resulted in breakthroughs in iPSC-based drug discovery, while Saudi Arabia’s Vision 2030 initiative prioritizes biotechnology under its economic diversification goals. Africa faces significant hurdles, including limited funding and underdeveloped healthcare infrastructure. Nonetheless, increasing international collaborations and rising chronic disease burdens suggest untapped long-term potential for iPSC services.
Report Scope
This market research report offers a holistic overview of global and regional markets for the forecast period 2025–2032. It presents accurate and actionable insights based on a blend of primary and secondary research.
Key Coverage Areas:
FREQUENTLY ASKED QUESTIONS:
What is the current market size of Global Induced Pluripotent Stem Cells Service Market?
-> Global induced pluripotent stem cells service market was valued at USD 2,450 million in 2023 and is projected to reach USD 5,109 million by 2030.
Which key companies operate in Global Induced Pluripotent Stem Cells Service Market?
-> Key players include Lonza, Thermo Fisher Scientific Inc., FUJIFILM Cellular Dynamics, Inc. (FCDI), Charles River Laboratories, Novo Holdings (Catalent, Inc), Creative Bioarray, Creative Biolabs, iXCells Biotechnologies, Creative Biogene, Axol Bioscience Ltd., among others.
What are the key growth drivers?
-> Key growth drivers include advancements in regenerative medicine, increasing R&D investments in stem cell therapies, and rising demand for personalized medicine.
Which region dominates the market?
-> North America holds the largest market share, while Asia-Pacific is expected to witness the highest growth rate during the forecast period.
What are the emerging trends?
-> Emerging trends include automation in cell culture processes, integration of AI in cell differentiation, and development of xeno-free culture media.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Induced Pluripotent Stem Cells Service Market Definition
1.2 Market Segments
1.2.1 Segment by Type
1.2.2 Segment by Application
1.3 Global Induced Pluripotent Stem Cells Service Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Induced Pluripotent Stem Cells Service Overall Market Size
2.1 Global Induced Pluripotent Stem Cells Service Market Size: 2023 VS 2030
2.2 Global Induced Pluripotent Stem Cells Service Market Size, Prospects & Forecasts: 2019-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Induced Pluripotent Stem Cells Service Players in Global Market
3.2 Top Global Induced Pluripotent Stem Cells Service Companies Ranked by Revenue
3.3 Global Induced Pluripotent Stem Cells Service Revenue by Companies
3.4 Top 3 and Top 5 Induced Pluripotent Stem Cells Service Companies in Global Market, by Revenue in 2023
3.5 Global Companies Induced Pluripotent Stem Cells Service Product Type
3.6 Tier 1, Tier 2, and Tier 3 Induced Pluripotent Stem Cells Service Players in Global Market
3.6.1 List of Global Tier 1 Induced Pluripotent Stem Cells Service Companies
3.6.2 List of Global Tier 2 and Tier 3 Induced Pluripotent Stem Cells Service Companies
4 Sights by Product
4.1 Overview
4.1.1 Segmentation by Type - Global Induced Pluripotent Stem Cells Service Market Size Markets, 2023 & 2030
4.1.2 iPSC Manufacturing Service
4.1.3 iPSC Reprogramming Service
4.1.4 iPSC Culture Service
4.1.5 iPSC Differentiation Service
4.1.6 iPSC Gene Editing Service
4.1.7 Other
4.2 Segmentation by Type - Global Induced Pluripotent Stem Cells Service Revenue & Forecasts
4.2.1 Segmentation by Type - Global Induced Pluripotent Stem Cells Service Revenue, 2019-2024
4.2.2 Segmentation by Type - Global Induced Pluripotent Stem Cells Service Revenue, 2025-2030
4.2.3 Segmentation by Type - Global Induced Pluripotent Stem Cells Service Revenue Market Share, 2019-2030
5 Sights by Application
5.1 Overview
5.1.1 Segmentation by Application - Global Induced Pluripotent Stem Cells Service Market Size, 2023 & 2030
5.1.2 Pharmaceutical Company
5.1.3 Laboratory
5.1.4 Scientific Research Institution
5.2 Segmentation by Application - Global Induced Pluripotent Stem Cells Service Revenue & Forecasts
5.2.1 Segmentation by Application - Global Induced Pluripotent Stem Cells Service Revenue, 2019-2024
5.2.2 Segmentation by Application - Global Induced Pluripotent Stem Cells Service Revenue, 2025-2030
5.2.3 Segmentation by Application - Global Induced Pluripotent Stem Cells Service Revenue Market Share, 2019-2030
6 Sights by Region
6.1 By Region - Global Induced Pluripotent Stem Cells Service Market Size, 2023 & 2030
6.2 By Region - Global Induced Pluripotent Stem Cells Service Revenue & Forecasts
6.2.1 By Region - Global Induced Pluripotent Stem Cells Service Revenue, 2019-2024
6.2.2 By Region - Global Induced Pluripotent Stem Cells Service Revenue, 2025-2030
6.2.3 By Region - Global Induced Pluripotent Stem Cells Service Revenue Market Share, 2019-2030
6.3 North America
6.3.1 By Country - North America Induced Pluripotent Stem Cells Service Revenue, 2019-2030
6.3.2 United States Induced Pluripotent Stem Cells Service Market Size, 2019-2030
6.3.3 Canada Induced Pluripotent Stem Cells Service Market Size, 2019-2030
6.3.4 Mexico Induced Pluripotent Stem Cells Service Market Size, 2019-2030
6.4 Europe
6.4.1 By Country - Europe Induced Pluripotent Stem Cells Service Revenue, 2019-2030
6.4.2 Germany Induced Pluripotent Stem Cells Service Market Size, 2019-2030
6.4.3 France Induced Pluripotent Stem Cells Service Market Size, 2019-2030
6.4.4 U.K. Induced Pluripotent Stem Cells Service Market Size, 2019-2030
6.4.5 Italy Induced Pluripotent Stem Cells Service Market Size, 2019-2030
6.4.6 Russia Induced Pluripotent Stem Cells Service Market Size, 2019-2030
6.4.7 Nordic Countries Induced Pluripotent Stem Cells Service Market Size, 2019-2030
6.4.8 Benelux Induced Pluripotent Stem Cells Service Market Size, 2019-2030
6.5 Asia
6.5.1 By Region - Asia Induced Pluripotent Stem Cells Service Revenue, 2019-2030
6.5.2 China Induced Pluripotent Stem Cells Service Market Size, 2019-2030
6.5.3 Japan Induced Pluripotent Stem Cells Service Market Size, 2019-2030
6.5.4 South Korea Induced Pluripotent Stem Cells Service Market Size, 2019-2030
6.5.5 Southeast Asia Induced Pluripotent Stem Cells Service Market Size, 2019-2030
6.5.6 India Induced Pluripotent Stem Cells Service Market Size, 2019-2030
6.6 South America
6.6.1 By Country - South America Induced Pluripotent Stem Cells Service Revenue, 2019-2030
6.6.2 Brazil Induced Pluripotent Stem Cells Service Market Size, 2019-2030
6.6.3 Argentina Induced Pluripotent Stem Cells Service Market Size, 2019-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Induced Pluripotent Stem Cells Service Revenue, 2019-2030
6.7.2 Turkey Induced Pluripotent Stem Cells Service Market Size, 2019-2030
6.7.3 Israel Induced Pluripotent Stem Cells Service Market Size, 2019-2030
6.7.4 Saudi Arabia Induced Pluripotent Stem Cells Service Market Size, 2019-2030
6.7.5 UAE Induced Pluripotent Stem Cells Service Market Size, 2019-2030
7 Companies Profiles
7.1 Lonza
7.1.1 Lonza Corporate Summary
7.1.2 Lonza Business Overview
7.1.3 Lonza Induced Pluripotent Stem Cells Service Major Product Offerings
7.1.4 Lonza Induced Pluripotent Stem Cells Service Revenue in Global Market (2019-2024)
7.1.5 Lonza Key News & Latest Developments
7.2 Thermo Fisher Scientific Inc.
7.2.1 Thermo Fisher Scientific Inc. Corporate Summary
7.2.2 Thermo Fisher Scientific Inc. Business Overview
7.2.3 Thermo Fisher Scientific Inc. Induced Pluripotent Stem Cells Service Major Product Offerings
7.2.4 Thermo Fisher Scientific Inc. Induced Pluripotent Stem Cells Service Revenue in Global Market (2019-2024)
7.2.5 Thermo Fisher Scientific Inc. Key News & Latest Developments
7.3 FUJIFILM Cellular Dynamics, Inc. (FCDI)
7.3.1 FUJIFILM Cellular Dynamics, Inc. (FCDI) Corporate Summary
7.3.2 FUJIFILM Cellular Dynamics, Inc. (FCDI) Business Overview
7.3.3 FUJIFILM Cellular Dynamics, Inc. (FCDI) Induced Pluripotent Stem Cells Service Major Product Offerings
7.3.4 FUJIFILM Cellular Dynamics, Inc. (FCDI) Induced Pluripotent Stem Cells Service Revenue in Global Market (2019-2024)
7.3.5 FUJIFILM Cellular Dynamics, Inc. (FCDI) Key News & Latest Developments
7.4 Charles River Laboratories
7.4.1 Charles River Laboratories Corporate Summary
7.4.2 Charles River Laboratories Business Overview
7.4.3 Charles River Laboratories Induced Pluripotent Stem Cells Service Major Product Offerings
7.4.4 Charles River Laboratories Induced Pluripotent Stem Cells Service Revenue in Global Market (2019-2024)
7.4.5 Charles River Laboratories Key News & Latest Developments
7.5 Novo Holdings (Catalent, Inc)
7.5.1 Novo Holdings (Catalent, Inc) Corporate Summary
7.5.2 Novo Holdings (Catalent, Inc) Business Overview
7.5.3 Novo Holdings (Catalent, Inc) Induced Pluripotent Stem Cells Service Major Product Offerings
7.5.4 Novo Holdings (Catalent, Inc) Induced Pluripotent Stem Cells Service Revenue in Global Market (2019-2024)
7.5.5 Novo Holdings (Catalent, Inc) Key News & Latest Developments
7.6 Creative Bioarray
7.6.1 Creative Bioarray Corporate Summary
7.6.2 Creative Bioarray Business Overview
7.6.3 Creative Bioarray Induced Pluripotent Stem Cells Service Major Product Offerings
7.6.4 Creative Bioarray Induced Pluripotent Stem Cells Service Revenue in Global Market (2019-2024)
7.6.5 Creative Bioarray Key News & Latest Developments
7.7 Creative Biolabs
7.7.1 Creative Biolabs Corporate Summary
7.7.2 Creative Biolabs Business Overview
7.7.3 Creative Biolabs Induced Pluripotent Stem Cells Service Major Product Offerings
7.7.4 Creative Biolabs Induced Pluripotent Stem Cells Service Revenue in Global Market (2019-2024)
7.7.5 Creative Biolabs Key News & Latest Developments
7.8 iXCells Biotechnologies
7.8.1 iXCells Biotechnologies Corporate Summary
7.8.2 iXCells Biotechnologies Business Overview
7.8.3 iXCells Biotechnologies Induced Pluripotent Stem Cells Service Major Product Offerings
7.8.4 iXCells Biotechnologies Induced Pluripotent Stem Cells Service Revenue in Global Market (2019-2024)
7.8.5 iXCells Biotechnologies Key News & Latest Developments
7.9 Creative Biogene
7.9.1 Creative Biogene Corporate Summary
7.9.2 Creative Biogene Business Overview
7.9.3 Creative Biogene Induced Pluripotent Stem Cells Service Major Product Offerings
7.9.4 Creative Biogene Induced Pluripotent Stem Cells Service Revenue in Global Market (2019-2024)
7.9.5 Creative Biogene Key News & Latest Developments
7.10 Axol Bioscience Ltd.
7.10.1 Axol Bioscience Ltd. Corporate Summary
7.10.2 Axol Bioscience Ltd. Business Overview
7.10.3 Axol Bioscience Ltd. Induced Pluripotent Stem Cells Service Major Product Offerings
7.10.4 Axol Bioscience Ltd. Induced Pluripotent Stem Cells Service Revenue in Global Market (2019-2024)
7.10.5 Axol Bioscience Ltd. Key News & Latest Developments
7.11 Elixirgen Scientific, Inc.
7.11.1 Elixirgen Scientific, Inc. Corporate Summary
7.11.2 Elixirgen Scientific, Inc. Business Overview
7.11.3 Elixirgen Scientific, Inc. Induced Pluripotent Stem Cells Service Major Product Offerings
7.11.4 Elixirgen Scientific, Inc. Induced Pluripotent Stem Cells Service Revenue in Global Market (2019-2024)
7.11.5 Elixirgen Scientific, Inc. Key News & Latest Developments
7.12 Cyagen
7.12.1 Cyagen Corporate Summary
7.12.2 Cyagen Business Overview
7.12.3 Cyagen Induced Pluripotent Stem Cells Service Major Product Offerings
7.12.4 Cyagen Induced Pluripotent Stem Cells Service Revenue in Global Market (2019-2024)
7.12.5 Cyagen Key News & Latest Developments
7.13 ALSTEM
7.13.1 ALSTEM Corporate Summary
7.13.2 ALSTEM Business Overview
7.13.3 ALSTEM Induced Pluripotent Stem Cells Service Major Product Offerings
7.13.4 ALSTEM Induced Pluripotent Stem Cells Service Revenue in Global Market (2019-2024)
7.13.5 ALSTEM Key News & Latest Developments
7.14 uBriGene Biosciences International Co.
7.14.1 uBriGene Biosciences International Co. Corporate Summary
7.14.2 uBriGene Biosciences International Co. Business Overview
7.14.3 uBriGene Biosciences International Co. Induced Pluripotent Stem Cells Service Major Product Offerings
7.14.4 uBriGene Biosciences International Co. Induced Pluripotent Stem Cells Service Revenue in Global Market (2019-2024)
7.14.5 uBriGene Biosciences International Co. Key News & Latest Developments
7.15 NEXEL Co., Ltd.
7.15.1 NEXEL Co., Ltd. Corporate Summary
7.15.2 NEXEL Co., Ltd. Business Overview
7.15.3 NEXEL Co., Ltd. Induced Pluripotent Stem Cells Service Major Product Offerings
7.15.4 NEXEL Co., Ltd. Induced Pluripotent Stem Cells Service Revenue in Global Market (2019-2024)
7.15.5 NEXEL Co., Ltd. Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Induced Pluripotent Stem Cells Service Market Opportunities & Trends in Global Market
Table 2. Induced Pluripotent Stem Cells Service Market Drivers in Global Market
Table 3. Induced Pluripotent Stem Cells Service Market Restraints in Global Market
Table 4. Key Players of Induced Pluripotent Stem Cells Service in Global Market
Table 5. Top Induced Pluripotent Stem Cells Service Players in Global Market, Ranking by Revenue (2023)
Table 6. Global Induced Pluripotent Stem Cells Service Revenue by Companies, (US$, Mn), 2019-2024
Table 7. Global Induced Pluripotent Stem Cells Service Revenue Share by Companies, 2019-2024
Table 8. Global Companies Induced Pluripotent Stem Cells Service Product Type
Table 9. List of Global Tier 1 Induced Pluripotent Stem Cells Service Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Induced Pluripotent Stem Cells Service Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 11. Segmentation by Type � Global Induced Pluripotent Stem Cells Service Revenue, (US$, Mn), 2023 & 2030
Table 12. Segmentation by Type - Global Induced Pluripotent Stem Cells Service Revenue (US$, Mn), 2019-2024
Table 13. Segmentation by Type - Global Induced Pluripotent Stem Cells Service Revenue (US$, Mn), 2025-2030
Table 14. Segmentation by Application� Global Induced Pluripotent Stem Cells Service Revenue, (US$, Mn), 2023 & 2030
Table 15. Segmentation by Application - Global Induced Pluripotent Stem Cells Service Revenue, (US$, Mn), 2019-2024
Table 16. Segmentation by Application - Global Induced Pluripotent Stem Cells Service Revenue, (US$, Mn), 2025-2030
Table 17. By Region� Global Induced Pluripotent Stem Cells Service Revenue, (US$, Mn), 2023 & 2030
Table 18. By Region - Global Induced Pluripotent Stem Cells Service Revenue, (US$, Mn), 2019-2024
Table 19. By Region - Global Induced Pluripotent Stem Cells Service Revenue, (US$, Mn), 2025-2030
Table 20. By Country - North America Induced Pluripotent Stem Cells Service Revenue, (US$, Mn), 2019-2024
Table 21. By Country - North America Induced Pluripotent Stem Cells Service Revenue, (US$, Mn), 2025-2030
Table 22. By Country - Europe Induced Pluripotent Stem Cells Service Revenue, (US$, Mn), 2019-2024
Table 23. By Country - Europe Induced Pluripotent Stem Cells Service Revenue, (US$, Mn), 2025-2030
Table 24. By Region - Asia Induced Pluripotent Stem Cells Service Revenue, (US$, Mn), 2019-2024
Table 25. By Region - Asia Induced Pluripotent Stem Cells Service Revenue, (US$, Mn), 2025-2030
Table 26. By Country - South America Induced Pluripotent Stem Cells Service Revenue, (US$, Mn), 2019-2024
Table 27. By Country - South America Induced Pluripotent Stem Cells Service Revenue, (US$, Mn), 2025-2030
Table 28. By Country - Middle East & Africa Induced Pluripotent Stem Cells Service Revenue, (US$, Mn), 2019-2024
Table 29. By Country - Middle East & Africa Induced Pluripotent Stem Cells Service Revenue, (US$, Mn), 2025-2030
Table 30. Lonza Corporate Summary
Table 31. Lonza Induced Pluripotent Stem Cells Service Product Offerings
Table 32. Lonza Induced Pluripotent Stem Cells Service Revenue (US$, Mn) & (2019-2024)
Table 33. Lonza Key News & Latest Developments
Table 34. Thermo Fisher Scientific Inc. Corporate Summary
Table 35. Thermo Fisher Scientific Inc. Induced Pluripotent Stem Cells Service Product Offerings
Table 36. Thermo Fisher Scientific Inc. Induced Pluripotent Stem Cells Service Revenue (US$, Mn) & (2019-2024)
Table 37. Thermo Fisher Scientific Inc. Key News & Latest Developments
Table 38. FUJIFILM Cellular Dynamics, Inc. (FCDI) Corporate Summary
Table 39. FUJIFILM Cellular Dynamics, Inc. (FCDI) Induced Pluripotent Stem Cells Service Product Offerings
Table 40. FUJIFILM Cellular Dynamics, Inc. (FCDI) Induced Pluripotent Stem Cells Service Revenue (US$, Mn) & (2019-2024)
Table 41. FUJIFILM Cellular Dynamics, Inc. (FCDI) Key News & Latest Developments
Table 42. Charles River Laboratories Corporate Summary
Table 43. Charles River Laboratories Induced Pluripotent Stem Cells Service Product Offerings
Table 44. Charles River Laboratories Induced Pluripotent Stem Cells Service Revenue (US$, Mn) & (2019-2024)
Table 45. Charles River Laboratories Key News & Latest Developments
Table 46. Novo Holdings (Catalent, Inc) Corporate Summary
Table 47. Novo Holdings (Catalent, Inc) Induced Pluripotent Stem Cells Service Product Offerings
Table 48. Novo Holdings (Catalent, Inc) Induced Pluripotent Stem Cells Service Revenue (US$, Mn) & (2019-2024)
Table 49. Novo Holdings (Catalent, Inc) Key News & Latest Developments
Table 50. Creative Bioarray Corporate Summary
Table 51. Creative Bioarray Induced Pluripotent Stem Cells Service Product Offerings
Table 52. Creative Bioarray Induced Pluripotent Stem Cells Service Revenue (US$, Mn) & (2019-2024)
Table 53. Creative Bioarray Key News & Latest Developments
Table 54. Creative Biolabs Corporate Summary
Table 55. Creative Biolabs Induced Pluripotent Stem Cells Service Product Offerings
Table 56. Creative Biolabs Induced Pluripotent Stem Cells Service Revenue (US$, Mn) & (2019-2024)
Table 57. Creative Biolabs Key News & Latest Developments
Table 58. iXCells Biotechnologies Corporate Summary
Table 59. iXCells Biotechnologies Induced Pluripotent Stem Cells Service Product Offerings
Table 60. iXCells Biotechnologies Induced Pluripotent Stem Cells Service Revenue (US$, Mn) & (2019-2024)
Table 61. iXCells Biotechnologies Key News & Latest Developments
Table 62. Creative Biogene Corporate Summary
Table 63. Creative Biogene Induced Pluripotent Stem Cells Service Product Offerings
Table 64. Creative Biogene Induced Pluripotent Stem Cells Service Revenue (US$, Mn) & (2019-2024)
Table 65. Creative Biogene Key News & Latest Developments
Table 66. Axol Bioscience Ltd. Corporate Summary
Table 67. Axol Bioscience Ltd. Induced Pluripotent Stem Cells Service Product Offerings
Table 68. Axol Bioscience Ltd. Induced Pluripotent Stem Cells Service Revenue (US$, Mn) & (2019-2024)
Table 69. Axol Bioscience Ltd. Key News & Latest Developments
Table 70. Elixirgen Scientific, Inc. Corporate Summary
Table 71. Elixirgen Scientific, Inc. Induced Pluripotent Stem Cells Service Product Offerings
Table 72. Elixirgen Scientific, Inc. Induced Pluripotent Stem Cells Service Revenue (US$, Mn) & (2019-2024)
Table 73. Elixirgen Scientific, Inc. Key News & Latest Developments
Table 74. Cyagen Corporate Summary
Table 75. Cyagen Induced Pluripotent Stem Cells Service Product Offerings
Table 76. Cyagen Induced Pluripotent Stem Cells Service Revenue (US$, Mn) & (2019-2024)
Table 77. Cyagen Key News & Latest Developments
Table 78. ALSTEM Corporate Summary
Table 79. ALSTEM Induced Pluripotent Stem Cells Service Product Offerings
Table 80. ALSTEM Induced Pluripotent Stem Cells Service Revenue (US$, Mn) & (2019-2024)
Table 81. ALSTEM Key News & Latest Developments
Table 82. uBriGene Biosciences International Co. Corporate Summary
Table 83. uBriGene Biosciences International Co. Induced Pluripotent Stem Cells Service Product Offerings
Table 84. uBriGene Biosciences International Co. Induced Pluripotent Stem Cells Service Revenue (US$, Mn) & (2019-2024)
Table 85. uBriGene Biosciences International Co. Key News & Latest Developments
Table 86. NEXEL Co., Ltd. Corporate Summary
Table 87. NEXEL Co., Ltd. Induced Pluripotent Stem Cells Service Product Offerings
Table 88. NEXEL Co., Ltd. Induced Pluripotent Stem Cells Service Revenue (US$, Mn) & (2019-2024)
Table 89. NEXEL Co., Ltd. Key News & Latest Developments
List of Figures
Figure 1. Induced Pluripotent Stem Cells Service Product Picture
Figure 2. Induced Pluripotent Stem Cells Service Segment by Type in 2023
Figure 3. Induced Pluripotent Stem Cells Service Segment by Application in 2023
Figure 4. Global Induced Pluripotent Stem Cells Service Market Overview: 2022
Figure 5. Key Caveats
Figure 6. Global Induced Pluripotent Stem Cells Service Market Size: 2023 VS 2030 (US$, Mn)
Figure 7. Global Induced Pluripotent Stem Cells Service Revenue: 2019-2030 (US$, Mn)
Figure 8. The Top 3 and 5 Players Market Share by Induced Pluripotent Stem Cells Service Revenue in 2023
Figure 9. Segmentation by Type � Global Induced Pluripotent Stem Cells Service Revenue, (US$, Mn), 2023 & 2030
Figure 10. Segmentation by Type - Global Induced Pluripotent Stem Cells Service Revenue Market Share, 2019-2030
Figure 11. Segmentation by Application � Global Induced Pluripotent Stem Cells Service Revenue, (US$, Mn), 2023 & 2030
Figure 12. Segmentation by Application - Global Induced Pluripotent Stem Cells Service Revenue Market Share, 2019-2030
Figure 13. By Region - Global Induced Pluripotent Stem Cells Service Revenue Market Share, 2019-2030
Figure 14. By Country - North America Induced Pluripotent Stem Cells Service Revenue Market Share, 2019-2030
Figure 15. United States Induced Pluripotent Stem Cells Service Revenue, (US$, Mn), 2019-2030
Figure 16. Canada Induced Pluripotent Stem Cells Service Revenue, (US$, Mn), 2019-2030
Figure 17. Mexico Induced Pluripotent Stem Cells Service Revenue, (US$, Mn), 2019-2030
Figure 18. By Country - Europe Induced Pluripotent Stem Cells Service Revenue Market Share, 2019-2030
Figure 19. Germany Induced Pluripotent Stem Cells Service Revenue, (US$, Mn), 2019-2030
Figure 20. France Induced Pluripotent Stem Cells Service Revenue, (US$, Mn), 2019-2030
Figure 21. U.K. Induced Pluripotent Stem Cells Service Revenue, (US$, Mn), 2019-2030
Figure 22. Italy Induced Pluripotent Stem Cells Service Revenue, (US$, Mn), 2019-2030
Figure 23. Russia Induced Pluripotent Stem Cells Service Revenue, (US$, Mn), 2019-2030
Figure 24. Nordic Countries Induced Pluripotent Stem Cells Service Revenue, (US$, Mn), 2019-2030
Figure 25. Benelux Induced Pluripotent Stem Cells Service Revenue, (US$, Mn), 2019-2030
Figure 26. By Region - Asia Induced Pluripotent Stem Cells Service Revenue Market Share, 2019-2030
Figure 27. China Induced Pluripotent Stem Cells Service Revenue, (US$, Mn), 2019-2030
Figure 28. Japan Induced Pluripotent Stem Cells Service Revenue, (US$, Mn), 2019-2030
Figure 29. South Korea Induced Pluripotent Stem Cells Service Revenue, (US$, Mn), 2019-2030
Figure 30. Southeast Asia Induced Pluripotent Stem Cells Service Revenue, (US$, Mn), 2019-2030
Figure 31. India Induced Pluripotent Stem Cells Service Revenue, (US$, Mn), 2019-2030
Figure 32. By Country - South America Induced Pluripotent Stem Cells Service Revenue Market Share, 2019-2030
Figure 33. Brazil Induced Pluripotent Stem Cells Service Revenue, (US$, Mn), 2019-2030
Figure 34. Argentina Induced Pluripotent Stem Cells Service Revenue, (US$, Mn), 2019-2030
Figure 35. By Country - Middle East & Africa Induced Pluripotent Stem Cells Service Revenue Market Share, 2019-2030
Figure 36. Turkey Induced Pluripotent Stem Cells Service Revenue, (US$, Mn), 2019-2030
Figure 37. Israel Induced Pluripotent Stem Cells Service Revenue, (US$, Mn), 2019-2030
Figure 38. Saudi Arabia Induced Pluripotent Stem Cells Service Revenue, (US$, Mn), 2019-2030
Figure 39. UAE Induced Pluripotent Stem Cells Service Revenue, (US$, Mn), 2019-2030
Figure 40. Lonza Induced Pluripotent Stem Cells Service Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 41. Thermo Fisher Scientific Inc. Induced Pluripotent Stem Cells Service Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 42. FUJIFILM Cellular Dynamics, Inc. (FCDI) Induced Pluripotent Stem Cells Service Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 43. Charles River Laboratories Induced Pluripotent Stem Cells Service Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 44. Novo Holdings (Catalent, Inc) Induced Pluripotent Stem Cells Service Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 45. Creative Bioarray Induced Pluripotent Stem Cells Service Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 46. Creative Biolabs Induced Pluripotent Stem Cells Service Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 47. iXCells Biotechnologies Induced Pluripotent Stem Cells Service Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 48. Creative Biogene Induced Pluripotent Stem Cells Service Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 49. Axol Bioscience Ltd. Induced Pluripotent Stem Cells Service Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 50. Elixirgen Scientific, Inc. Induced Pluripotent Stem Cells Service Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 51. Cyagen Induced Pluripotent Stem Cells Service Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 52. ALSTEM Induced Pluripotent Stem Cells Service Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 53. uBriGene Biosciences International Co. Induced Pluripotent Stem Cells Service Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 54. NEXEL Co., Ltd. Induced Pluripotent Stem Cells Service Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
